Eagle’s Eye View: What are the Benefits of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia?
In this week’s View, Dr. Eagle explores a UK Biobank study on triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease. He then discusses the risk of atrial and ventricular arrhythmia comparing carvedilol versus metoprolol among implantable cardioverter defibrillator recipients. Finally, Dr. Eagle examines the results from the ORION-5 randomized clinical trial that looked at the efficacy, safety, and tolerability of inclisiran in patients with homozygous familial hypercholesterolemia.
Twitter Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Arrhythmias and Clinical EP, Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Prevention, Implantable Devices, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Homozygous Familial Hypercholesterolemia, Hypertriglyceridemia, Lipid Metabolism, Nonstatins, Acute Heart Failure
Keywords: EaglesEyeView, Apolipoproteins B, Dyslipidemias, Triglycerides, Adrenergic beta-Antagonists, Arrhythmias, Cardiac, Defibrillators, Implantable, Heart Failure, Primary Prevention, Cholesterol, LDL, Hypercholesterolemia
< Back to Listings
